This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
DAIC
MAY 6, 2024
Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,
Medical Xpress - Cardiology
SEPTEMBER 20, 2024
For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ventricular (LV) diastolic function, according to a study published online Sept. 9 in Circulation: Heart Failure.
Circulation
APRIL 6, 2025
Circulation, Volume 151, Issue 14 , Page 990-992, April 8, 2025.
Circulation
JANUARY 22, 2025
Circulation, Ahead of Print.
Circulation: Heart Failure
OCTOBER 23, 2023
Circulation: Heart Failure, Volume 16, Issue 11 , Page e010633, November 1, 2023. BACKGROUND:Heart failure with preserved ejection fraction is associated with significant functional limitations, yet treatments for improving exercise performance have been elusive.
Circulation: Heart Failure
JANUARY 28, 2025
Circulation: Heart Failure, Ahead of Print. BACKGROUND:The therapeutic armamentarium for heart failure with preserved ejection fraction (HFpEF) remains notably constrained.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4121812-A4121812, November 12, 2024. Background:Heart failure (HF) with preserved ejection fraction (HFpEF) is a complex syndrome characterized by heterogeneous pathophysiology and dynamic changes in cardiac structure and function.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4118341-A4118341, November 12, 2024. As heart failure with preserved ejection fraction (HFpEF) comprises half of all heart failure cases, understanding its management and effect on outcomes is crucial.
Circulation: Heart Failure
FEBRUARY 1, 2024
Circulation: Heart Failure, Ahead of Print. Background:NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels are variably elevated in heart failure with preserved ejection fraction (HFpEF), even in the presence of increased left ventricular filling pressures.
Circulation
AUGUST 4, 2024
Circulation, Volume 150, Issue 6 , Page e106-e106, August 6, 2024.
Circulation
NOVEMBER 10, 2024
Circulation, Volume 150, Issue 20 , Page 1584-1587, November 12, 2024.
Circulation
MARCH 9, 2025
Circulation, Volume 151, Issue 10 , Page e686-e686, March 11, 2025.
Circulation
SEPTEMBER 2, 2024
Circulation, Volume 150, Issue 10 , Page e224-e225, September 3, 2024.
Circulation
AUGUST 4, 2024
Circulation, Volume 150, Issue 6 , Page e107-e108, August 6, 2024.
Circulation
MARCH 16, 2025
Circulation, Volume 151, Issue 11 , Page e763-e763, March 18, 2025.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4120990-A4120990, November 12, 2024. Background:Recent advancements have seen deep learning models help differentiate echocardiography images of patients with heart failure with preserved ejection fraction (HFpEF) from normal controls.
Circulation
FEBRUARY 9, 2025
Circulation, Volume 151, Issue 6 , Page e37-e37, February 11, 2025.
Circulation
FEBRUARY 9, 2025
Circulation, Volume 151, Issue 6 , Page e38-e38, February 11, 2025.
Circulation: Heart Failure
DECEMBER 6, 2024
Circulation: Heart Failure, Ahead of Print. In heart failure with reduced ejection fraction, exercise stimulates a reflex increase in muscle sympathetic nerve activity (MSNA) that relates inversely to peak oxygen uptake (VO2peak). BACKGROUND:In heart failure, sympathetic excess and exercise intolerance impair quality of life.
Circulation: Heart Failure
DECEMBER 1, 2023
Circulation: Heart Failure, Ahead of Print.
Circulation: Heart Failure
NOVEMBER 25, 2024
Circulation: Heart Failure, Volume 17, Issue 12 , Page e011629, December 1, 2024. Spironolactone reduced HF events in some patients with HF with preserved ejection fraction, but the results were not generalizable to all patients with HF with preserved ejection fraction.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4141446-A4141446, November 12, 2024. Emerging evidence suggests that vascular stress from cardiovascular-related co-morbidities promotes microvascular dysfunction, a key component in the development of heart failure with preserved ejection fraction.
JAMA Cardiology
JULY 23, 2024
Among patients with heart failure with preserved ejection fraction (HFpEF), right ventricular (RV) dysfunction is strongly associated with an increased risk of morbidity and mortality.
Circulation: Heart Failure
DECEMBER 18, 2023
Circulation: Heart Failure, Ahead of Print. We aimed to assess absolute coronary flow, absolute microvascular resistance, myocardial perfusion, coronary flow reserve, and microvascular resistance reserve in patients with HF with preserved ejection fraction and HF with reduced ejection fraction (HFrEF).METHODS:Single-center,
Circulation: Heart Failure
SEPTEMBER 27, 2023
Circulation: Heart Failure, Volume 16, Issue 11 , Page e010849, November 1, 2023. 1.81]), incident HF with preserved ejection fraction (1.44 [95% CI, 1.07–1.94]), 1.94]), incident heart failure with reduced ejection fraction (1.48 [95% CI, 1.08–2.02]), 2.02]), and incident AF (1.44 [95% CI, 1.18–1.77])
Circulation: Cardiovascular Quality & Outcomes
APRIL 21, 2025
Circulation: Cardiovascular Quality and Outcomes, Ahead of Print. BACKGROUND:Assessing the generalizability of randomized clinical trials (RCTs) to real-world patients remains challenging.
Circulation: Heart Failure
DECEMBER 18, 2023
Circulation: Heart Failure, Volume 16, Issue 12 , Page e010673, December 1, 2023. mm Hg in HF with preserved ejection fraction patients and was also exacerbated by exercise. BACKGROUND:Twitch-independent tension has been demonstrated in cardiomyocytes, but its role in heart failure (HF) is unclear. P<0.001).
European Journal of Heart Failure
OCTOBER 17, 2023
HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction. Associations of colchicine-related plasma proteins, incident heart failure (HF) and cardiac structure and function.
Circulation
APRIL 1, 2025
Circulation, Ahead of Print. BACKGROUND:Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but effective treatments are lacking. Cardiac lymphatics play a crucial role in maintaining heart health by draining fluids and immune cells.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4140591-A4140591, November 12, 2024.
Circulation
DECEMBER 21, 2023
Circulation, Ahead of Print. BACKGROUND:Metabolic distress is often associated with heart failure with preserved ejection fraction (HFpEF) and represents a therapeutic challenge. Metabolism-induced systemic inflammation links comorbidities with HFpEF.
Circulation: Cardiovascular Imaging
JANUARY 13, 2025
Circulation: Cardiovascular Imaging, Ahead of Print. BACKGROUND:In patients with heart failure with preserved ejection fraction (HFpEF), the impact of type 2 diabetes (T2D) on left ventricular global longitudinal strain (LV GLS) and its prognostic implications remains unclear.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4123391-A4123391, November 12, 2024. The CardioMEMS PA (pulmonary artery) sensor allows remote pulmonary artery diastolic (PAD) pressure monitoring to adjust diuresis in heart failure with preserved ejection fraction (HFpEF).
Dr. S. Venkatesan MD
AUGUST 3, 2024
Gorter TM, van Veldhuisen DJ, Bauersachs et al Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Fellows must be familiar with at-least half of them.( RIMP is less practical and error prone can be ignored) Reference 1. Eur J Heart Fail. 2018 Jan;20(1):16-37.
Circulation: Heart Failure
MARCH 1, 2024
Circulation: Heart Failure, Ahead of Print. BACKGROUND:Older adults have markedly increased risks of heart failure (HF), specifically HF with preserved ejection fraction (HFpEF). Identifying novel biomarkers can help in understanding HF pathogenesis and improve at-risk population identification.
European Journal of Heart Failure
NOVEMBER 8, 2023
Abstract Aim To examine the ability of serum proteins in predicting future heart failure (HF) events, including HF with reduced or preserved ejection fraction (HFrEF or HFpEF), in relation to event time, and with or without considering established HF-associated clinical variables.
Circulation: Heart Failure
SEPTEMBER 12, 2023
Circulation: Heart Failure, Volume 16, Issue 11 , Page e010618, November 1, 2023. BACKGROUND:Obesity and adiposity are associated with an increased risk of heart failure with preserved ejection fraction (HFpEF); yet, specific underlying mechanisms remain unclear.
40 Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4139791-A4139791, November 12, 2024. Intro:Drug Development for Heart failure with Preserved Ejection Fraction (HFpEF) is a major challenge facing cardiovascular research due to its complex pathophysiology and existence of comorbidities, leading to recognize distinct HFpEF phenogroups.
40 Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4134456-A4134456, November 12, 2024. Introduction:Heart failure with preserved ejection fraction (HFpEF) is a form of heart failure which is rapidly rising in incidence in the US today. Despite this, no therapies with mortality benefit exist for this syndrome.
European Journal of Heart Failure
APRIL 6, 2025
The aim of this study was to examine whether circulating peroxiredoxin-4 (Prx4), a marker of systemic oxidative stress, associates with incident HF and its subtypes. During a median follow-up of 12.6years, 349 (4.3%) HF events occurred of which 118 (33.8%) had HF with preserved ejection fraction.
Circulation
DECEMBER 7, 2023
Circulation, Ahead of Print. BACKGROUND:Sodium-glucose cotransporter 2 inhibitors reduce the risk of worsening heart failure (HF) and cardiovascular death in patients with HF irrespective of left ventricular ejection fraction. Dapagliflozin did not improve these outcomes in patients with HF with preserved ejection fraction.
Circulation
OCTOBER 13, 2023
Circulation, Volume 148, Issue 24 , Page 1945-1957, December 12, 2023. BACKGROUND:Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heart failure with mildly reduced or preserved ejection fraction.
Circulation: Heart Failure
OCTOBER 23, 2023
Circulation: Heart Failure, Volume 16, Issue 11 , Page e010802, November 1, 2023. Heart failure with preserved ejection fraction (HFpEF) has become the leading form of heart failure worldwide, particularly among elderly patient populations.
Circulation
NOVEMBER 17, 2024
Circulation, Ahead of Print. Background: Patients with heart failure, a preserved ejection fraction (HFpEF), and obesity have significant disability and suffer frequent exacerbations of heart failure.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content